BriaCell Therapeutics Corp. (TSX: BCT)
Health Care · Biotechnology · CA
CA$5.56
-3.30% today · -68.4% 1Y
BriaCell Therapeutics Corp. (TSX: BCT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $35.09M and employs 17 people.
Over the last twelve months the share price has lost 68.4%, trading between 3.68 and 20.40.
Tweenvest scores BriaCell Therapeutics Corp. across four factors: quality 35/100, value 40/100. Its strongest factor is value.
BCT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $35.09M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -9.66
- Dividend yield
- —
- Beta (5Y)
- 1.51
- 52-week high
- CA$20.40
- 52-week low
- CA$3.68
- Avg volume (3M)
- —
- Shares outstanding
- 8.70M
- Employees
- 17
- Next earnings
- —
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
- ISIN
- CA1079303071
- Listed since
- Aug 13, 2012
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| TMS Co., Ltd.TSE: 4891 | $36.48M | ¥126.00 | -5.97% |
| Enimmune CorporationTPEX: 6564 | $36.23M | NT$16.00 | -3.61% |
| Arecor Therapeutics plcAIM: AREC | $36.22M | £0.73 | 0.00% |
| AIxCrypto Holdings, Inc.NasdaqCM: AIXC | $35.82M | $1.77 | -1.12% |
| Aligos Therapeutics, Inc.NasdaqCM: ALGS | $34.59M | $5.31 | -4.15% |
| Organoidsciences Ltd.KOSDAQ: A476040 | $34.52M | ₩7,060.00 | +4.28% |
| Elutia Inc.NasdaqCM: ELUT | $34.49M | $0.83 | +6.24% |
| QuantaMatrix Inc.KOSDAQ: A317690 | $34.46M | ₩2,305.00 | +5.25% |
Figures last refreshed Oct 4, 2026.